Aclaris Therapeutics, Inc. - ACRS STOCK NEWS

Aclaris Therapeutics, Inc. (Nasdaq: ACRS) announced a public offering of 7,042,254 shares at $17.75 each, with expected gross proceeds of approximately $125 million. The underwriters have a 30-day option to purchase an additional 1,056,338 shares at the public offering price. The offering is set to close around June 14, 2021, pending customary conditions. Jefferies LLC, SVB Leerink LLC, and Piper Sandler & Co. serve as joint book-running managers. A registration statement was filed with the SEC, and details can be found in the prospectus available on the SEC's website.

Aclaris Therapeutics, Inc. (Nasdaq: ACRS) announced plans for a public offering of $75 million in common stock, subject to market conditions. The company will offer up to an additional 15% of shares through a 30-day underwriter option. Jefferies LLC, SVB Leerink LLC, and Piper Sandler & Co. are leading the offering, with a registration statement already filed and effective as of May 20, 2021. The offering aims to generate funds for Aclaris' drug development pipeline targeting immuno-inflammatory diseases. However, there's no assurance of completion or specifics regarding the offering.

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced positive preliminary results from its Phase 2a trial of ATI-1777, a topical JAK inhibitor for moderate to severe atopic dermatitis. The trial showed a statistically significant reduction in the modified Eczema Area and Severity Index (mEASI) score by 74.4% in the ATI-1777 group compared to 41.4% in the control. The drug was generally well tolerated with no serious adverse events. Aclaris plans to advance ATI-1777 to Phase 2b development following these findings. Management will discuss the results in a conference call today at 8 AM ET.

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that Dr. Neal Walker, President and CEO, will present at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 1:00 p.m. ET. This presentation will provide an overview of the company's efforts in developing innovative drug candidates for immuno-inflammatory diseases. Aclaris' management will also be available for virtual one-on-one meetings throughout June 1st. The presentation can be viewed live on Aclaris' website, and the archive will be accessible for 30 days.

Aclaris Therapeutics (NASDAQ: ACRS) reported Q1 2021 results with a net loss of $28.8 million, up from $15.6 million in Q1 2020. Total revenue increased to $1.8 million from $1.4 million. The company holds $142.7 million in cash and equivalents, sufficient to fund operations through 2023. Aclaris is advancing its drug pipeline with a Phase 2b trial for ATI-450 in rheumatoid arthritis and two additional trials for hidradenitis suppurativa and psoriatic arthritis. Results from the Phase 2a trial of ATI-1777 for atopic dermatitis are expected in Q2 2021.

Aclaris Therapeutics (NASDAQ: ACRS) has completed enrollment in its Phase 2a clinical trial of ATI-1777, a topical JAK 1/3 inhibitor for treating moderate to severe atopic dermatitis. The trial, which is randomized and double-blind, aims to assess the drug's efficacy and safety. Results are anticipated by mid-2021. This milestone follows positive preliminary results from another trial of ATI-450 for rheumatoid arthritis. Aclaris continues to develop treatments targeting immuno-inflammatory diseases and aims to demonstrate ATI-1777's potential while minimizing systemic exposure.

Aclaris Therapeutics (NASDAQ: ACRS) announced promising preliminary topline data for ATI-450, an oral MK2 inhibitor, from its Phase 2a trial in moderate to severe rheumatoid arthritis. This investigational drug showed significant clinical activity with sustained reductions in DAS28-CRP scores and enhanced inflammatory biomarker suppression over 12 weeks. For Q4 2020, Aclaris reported a net loss of $13.2 million, a decrease from $18.6 million in Q4 2019, along with total revenues of $1.6 million. Following a public offering in January 2021, Aclaris secured $103.5 million to strengthen its balance sheet.

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that Dr. Neal Walker, President and CEO, will present at two upcoming virtual investor conferences. The presentations include the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 a.m. ET, and the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 10:00 a.m. ET. Management will also be available for virtual one-on-one meetings on both days. Webcasts of the presentations can be accessed on Aclaris' website and will be archived for 30 days.

Aclaris Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021. Management will engage in a virtual fireside chat at 8:00 a.m. ET and will be available for one-on-one meetings throughout the day. Investors can access a live audio webcast of the chat on the company's website, which will be archived for 30 days. Aclaris focuses on developing innovative drug candidates for immuno-inflammatory diseases, leveraging a strong R&D pipeline.